Scientists from the University of Sheffield have found that genetic mutations in MRSA allow it to evolve and become more resistant to antibiotics such as penicillin.
The research, published in PLOS Pathogens, found that genetic mutations in MRSA are allowing the bacteria to become highly resistant to antibiotics without reducing the bacteria's ability to cause disease.
Most clinical MRSA exhibits a low level of antibiotic resistance, due to the cells acquiring a new gene encoding a protein (MecA) that makes its cell wall, some strains can evolve high-level resistance and pose a serious threat.
Antibiotics, such as penicillin and methicillin, do not bind well to the new protein (MecA) meaning they cannot 'kill' the bacteria. The next phase of this research is to understand how this protein works with other factors within the bacteria to allow a higher level of antibiotic resistance.
Findings from the research pave the way for more understanding of the cause and evolution of antibiotic resistance, and will help researchers develop new treatments and drugs for MRSA.
Simon Foster, Professor of Molecular Microbiology at the University and Principal Investigator of the research, said: "Antibiotics have been a mainstay of human healthcare for over 70 years, but the emergence of antimicrobial resistance is now a global catastrophe. In order to combat antimicrobial resistant organisms, we have to understand them. Our work uncovers the complex mechanisms that underpin resistance, giving insight into how we might tackle this global challenge."
The research is part of a collaborative project called the Physics of Antimicrobial Resistance which involves the Universities of Sheffield, Newcastle, Edinburgh and Cambridge, funded by UK Research and Innovation (UKRI).
Dr Viralkumar Panchal, Postdoctoral Researcher at the University of Sheffield and leader of the research, said: "The research provides a new outlook into the process of evolution of resistance and reveals important details of how MRSA is so resistant. We can now exploit these findings to develop new cures."
Globally, the effectiveness of antimicrobial compounds is decreasing as infectious species become increasingly resistant. The University of Sheffield's Florey Institute for Host-Pathogen Interactions aims to create a world-leading focus on antimicrobial resistance from fundamental science to translation and brings together scientists and clinicians to tackle this problem.
For further information please contact: Emma Griffiths, Media and PR Assistant, University of Sheffield, 0114 222 1034, email@example.com
Notes to editors
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities.
A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.